Additional Resources
New data regarding the prevention, diagnosis, and management of COVID-19 are emerging daily. Please see the list of COVID-19 resources for healthcare professionals provided below for additional up-to-date and comprehensive information.
Managing Patients with COVID-19
- National Infusion Center Association (NICA). COVID-19 Antibody Therapy Resource Center. Accessed June 3, 2022. https://infusioncenter.org/infusion_resources/covid-19-antibody-treatment-resource-center/
- Department of Health and Human Services (HHS). CombatCOVID. COVID-19 Treatments. https://combatcovid.hhs.gov/
- National Institutes of Health (NIH). COVID-19 Treatment Guidelines. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Accessed June 6, 2022. https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf
- Centers for Disease Control and Prevention (CDC). Clinical Care Considerations. Updated May 27, 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/clinical-considerations-index.html
- World Health Organization (WHO). Country & Technical Guidance – coronavirus disease (COVID-19). Accessed June 5, 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance
- Society of Critical Care Medicine. Surviving Sepsis Campaign: COVID-19 guidelines. https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19
- Infectious Disease Society of America (IDSA). IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Last updated May 27, 2022. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
Prescribing Information and factsheets for healthcare providers
- VEKLURY® (remdesivir). Prescribing information. Gilead Sciences, Inc; 2022. https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf
- OLUMIANT (baricitinib). Prescribing information. Eli Lilly and Company; 2022. https://pi.lilly.com/us/olumiant-uspi.pdf
- US Food and Drug Administration (FDA). Emergency use authorization (EUA) for ACTEMRA® (tocilizumab). https://www.fda.gov/media/150321/download
- US Food and Drug Administration (FDA). Emergency use authorization (EUA) for bebtelovimab. https://www.fda.gov/media/156152/download
- US Food and Drug Administration (FDA). Emergency use authorization (EUA) for PAXLOVID™ (nirmatrelvir/ritonavir). https://www.fda.gov/media/155050/download
- US Food and Drug Administration (FDA). Emergency use authorization (EUA) for LAGEVRIO™ (molnupiravir). https://www.fda.gov/media/155054/download